Company Encyclopedia
View More
name
Impedimed Limited
IPD.AU
News
View More

ImpediMed Director Increases Shareholding in Strategic Move

Impedimed Limited (AU:IPD) announced that director Andrew Grant increased his shareholding by acquiring 98,347 ordinary shares, using 15% of his director fees for Q3 2025. This strategic move aligns his interests with the company's performance, potentially boosting stakeholder confidence. The latest analyst rating for AU:IPD is a Buy with a price target of A$0.13. ImpediMed specializes in non-invasive medical devices, focusing on fluid status and tissue composition measurement.

Tip Ranks·
Tip Ranks·

Impedimed Limited (IPDQF) Receives a Buy from Morgans

Morgans analyst Scott Power has maintained a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.13, while the shares closed at A$0.04. Power has an average return of -1.5% and a 41.18% success rate. Additionally, Canaccord Genuity's Shane Storey also issued a Buy rating on October 31, but TR | OpenAI reiterated a Hold rating on the same day.

Tip Ranks·
Tip Ranks·

Impedimed Limited Issues Shares to Non-Executive Directors

Impedimed Limited has issued 438,223 ordinary shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending September 30, 2025. This initiative aims to align directors' interests with shareholders, potentially enhancing market perception and stakeholder confidence. The current analyst rating for Impedimed Limited (AU:IPD) is a Buy, with a price target of A$0.07. The company operates in the medical technology sector, focusing on non-invasive medical devices for fluid status assessment.

Tip Ranks·
Tip Ranks·

Canaccord Genuity Sticks to Their Buy Rating for Impedimed Limited (IPDQF)

Storey covers the Healthcare sector, focusing on stocks such as Somnomed Limited, Impedimed Limited, and CSL. According to TipRanks, Storey has an average return of 9.0% and a 52.36% success rate on recommended stocks. Currently, the analyst consensus on Impedimed Limited is a Strong Buy with an average price target of $0.07.

Tip Ranks·
Tip Ranks·

Impedimed Limited’s Earnings Call: Mixed Sentiments and Strategic Insights

Impedimed Limited's earnings call revealed mixed sentiments, celebrating a 33% year-on-year revenue growth to $3.6 million and increased reimbursement coverage for its BIS technology. However, challenges included an 11% decline in cash receipts, underwhelming U.S. sales, and concerns over operating cash flow sustainability. The company remains optimistic about future growth, particularly in heart failure and body composition markets, supported by a cash balance of $23 million. Despite hurdles, Impedimed aims for strategic expansions and financial discipline to enhance revenue.

Tip Ranks·
Tip Ranks·